Gemifloxacin Mesylate is a reliable and effectual antibiotic. Known as Factive, which is marketed by LG Life Sciences, the patent for gemifloxacin mesylate is due to expire on June 15, 2015. This once daily, 320 milligram tablet is the only FDA approved drug indicated for the treatment of acute bacterial exacerbation of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. Gemifloxican is also efficacious for the treatment of Community-acquired pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains), Haemophilus influenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, Chlamydia pneumoniae, or Klebsiella pneumoniae. The healing properties of gemifloxacin are far reaching, as this powerhouse antibiotic has in vitro activity against a vast range of Gram-negative and Gram-positive microorganisms. Gemifloxacin mesylate works by inhibiting DNA synthesis, through the inhibition of the DNA topoisomerase IV and gyrase, which are both required for bacterial growth.
Recorded sales of the brand name Factive, or gemifloxacin mesylate, reached roughly 6.3 million dollars in the U.S. in the 2011 year. Merus Labs International has currently completed the acquisition of the North American product rights for Factive (Gemifloxacin Mesylate) tablets from Cornerstone Therapeutics Inc., although this drug has not yet been commercialized in Canada. The unique ability of gemifloxacin to treat multi-drug resistant Streptococcus pneumoniae, makes it a necessary drug to have on hand. With the influx of resistant strains of bacteria, gemifloxacin is a formidable opponent for these strains. Gemifloxacin mesylate is effective for treating penicillin-resistant Streptococcus pneumoniae, which is considered to be strains resistant to two or greater of the drugs penicillins, cephalosporins, macrolides, tetracyclines or trimethoprim/sulfamethoxazole antibiotics.
There is a slight risk for patients taking gemifloxacin to develop tendonitis. For the aforementioned bacterial infections the typical dose is one 320 milligram tablet, to be taken for 5 to 7 days. Gemifloxacin may be taken with or without food, and patients should drink plenty of fluids when taking this drug. Exposure to the sun should be avoided while taking gemifloxacin. Side effects may include a rash, diarrhea, nausea, dizziness, nausea, vomiting or abdominal pain. Patients with a history of myasthenia gravis, or with an allergy to flouroquinolones should not take gemifloxacin mesylate. Clinical studies completed to determine the safety and efficacy of gemifloxacin revealed that the majority of patients who experienced adverse reactions in clinical trials deemed them mild or moderate. These comprehensive trials involved 8,119 patients who received daily oral doses of 320 milligrams of gemifloxacin. In addition to this promising news regarding the tolerability and safety profile of gemifloxacin, recent research worldwide has been focusing on the use of gemifloxacin for resistant bacteria. For example, a study released in the June 2012 issue of Helicobacter offered reassuring data which showed the ability of gemifloxacin to partially overcome quinolone resistance in patients with both H. pylori and a gryA mutation. This study, which was conducted in Taiwan is indicative of the future of research for antibiotics which will meet the need for fighting resistant bacteria. With the Centers for Disease Control citing that more than 70 percent of the bacteria which cause hospital-acquired infections being resistant to at least one of the antibiotics most commonly used to treat them, it is urgent that formulations of gemifloxacin, as well as other antibiotics be explored.
LGM Pharma provides Gemifloxacin Mesylate, CAS# 210353-53-0 for research and development purposes, and offers clients support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.